The Recovery Stack, Explained

Recovery is not a single system. When researchers talk about how the body handles physical load, oxidative stress and immune demand, they are describing several overlapping processes: antioxidant defence, the normal inflammatory response and its resolution, and the day-to-day chemistry of the gut. This guide walks through four compounds that have each been studied in that context (glutathione, vitamin C, specialised pro-resolving mediators and binders) and explains a detail that is easy to overlook: with several of these molecules, how they are delivered changes how much actually reaches the bloodstream. For New Zealanders researching recovery or immune-support supplements, this is the evidence picture, minus the hype.

None of what follows is advice about treating a condition. It is a plain-language tour of what the research literature describes, written for readers who want to understand the mechanisms before they understand the products.

Glutathione: the "master antioxidant" and why the label sticks

Glutathione is a small tripeptide, three amino acids (cysteine, glutamate and glycine), that the body synthesises in nearly every cell. It is often called the master antioxidant, and the nickname is earned. In research, glutathione does several jobs at once: it neutralises reactive oxygen species directly, it regenerates other antioxidants such as vitamins C and E back to their active forms, and it participates in the enzymatic pathways the body uses to process a wide range of compounds. Cellular glutathione status is one of the markers scientists reach for when they want a read on oxidative balance.

The catch is bioavailability. Glutathione taken as a conventional capsule is largely broken apart by digestive enzymes before it can be absorbed intact. The gut handles the tripeptide as food and cleaves it into its constituent amino acids. That is why researchers have spent considerable effort on delivery formats that protect the intact molecule.

One approach is liposomal encapsulation combined with sublingual dosing. Quicksilver's Liposomal Glutathione Complex wraps reduced glutathione in a phospholipid nanoemulsion held under the tongue, where the intact tripeptide can cross the oral mucosa rather than run the gauntlet of gut enzymes. The rationale, supported by absorption research on liposomal carriers, is straightforward: get more of the intact molecule into circulation than an equivalent capsule dose would allow.

Vitamin C: a self-limiting nutrient

Vitamin C is one of the most-studied nutrients in existence, and its roles are well characterised. It is required for the synthesis of collagen, and therefore for the normal formation of skin, cartilage and blood vessels, and research associates it with the function of several immune cell types. It is also a water-soluble antioxidant in its own right.

Here the interesting problem is not stability but a ceiling on absorption. Standard oral vitamin C is taken up through a saturable active-transport system in the gut. Below a certain intake, absorption is efficient; push the dose higher and the transporters saturate, so the fraction absorbed falls and the excess is simply passed. This is why swallowing progressively larger tablets yields diminishing returns. The plateau is built into the physiology.

Liposomal delivery is one way researchers have tried to work around that ceiling. Quicksilver's Liposomal Vitamin C supplies vitamin C as sodium ascorbate encapsulated in phospholipid liposomes, delivering 1000 mg per dose in a format designed to bypass the saturable transport step that limits standard oral vitamin C at higher intakes. The goal is not a different vitamin. It is a different route to the same molecule, aimed at the absorption bottleneck the research describes.

Inflammation has an off-switch: specialised pro-resolving mediators

This is the part of the recovery picture that has changed most in the last decade of research, so it is worth slowing down.

For a long time inflammation was framed as something that simply switched on and then faded away passively. The current understanding is quite different. The body's normal inflammatory response has two active phases: an initiation phase, and a distinct resolution phase in which the process is actively switched off and tissue returns to baseline. Resolution is not the absence of inflammation. It is its own coordinated programme, with its own signalling molecules.

Chief among those molecules are the specialised pro-resolving mediators, or SPMs, a family that includes resolvins, protectins and maresins. What makes them notable is where they come from: the body builds them enzymatically from the omega-3 fatty acids EPA and DHA, the same fats found in fish oil. In other words, part of what omega-3s do in research they do by being converted into these downstream resolution signals.

The biosynthesis is worth understanding because it explains why simply taking more precursor is not the same as having more finished mediator. Foundational work from the Serhan laboratory mapped how DHA is converted, step by step through specific lipoxygenase enzymes, into the protectin and maresin families, a tightly regulated enzymatic cascade rather than a passive conversion. That enzymatic dependency is a plausible rate-limiting step: the raw material can be abundant while the conversion to active resolution signals lags. It is exactly this gap between precursor availability and finished-mediator supply that the research on direct SPM administration sets out to probe.

That mechanism reframes a common supplement. Fish oil supplies the precursors; SPMs are the finished mediators. Metagenics SPM Active supplies specialised pro-resolving mediators directly rather than relying on the body to manufacture them from precursor fish oil. It is a more targeted option that has been studied in the context of the resolution phase of the normal inflammatory response, recovery and healthy ageing.

The compliance-critical point, and the honest scientific one, is the same: SPMs are studied for their role in resolving the body's normal inflammatory response, not in suppressing or blocking it. Resolution and inhibition are different processes, and the research is careful to distinguish them.

Why "resolution" is not "anti-inflammatory"

It is tempting to file SPMs under "anti-inflammatory," but that misses what the research actually describes. Anti-inflammatory agents typically dampen the initiation of the response. Resolution mediators work at the other end, helping coordinate the orderly wind-down and clearance that follows a normal inflammatory event. Understanding the difference is the whole reason this category exists as something separate from a general omega-3.

Binders: chemistry in the gut lumen

The fourth compound sits apart from the others, and it is the one most often misunderstood, so precision matters here.

Binders are compounds that adsorb other substances onto their surface within the gastrointestinal tract. Adsorption, molecules sticking to a surface, is a physical, chemical process, and it happens in the gut lumen, not in the bloodstream. Different binders present different surfaces and therefore have affinity for different classes of compound: activated charcoal is a high-surface-area carbon; zeolite and bentonite are aluminosilicate lattices with porous, mineral structures; chitosan carries a positive charge that attracts negatively charged molecules.

That variety is the logic behind a broad-spectrum blend. Quicksilver's Ultra Binder combines zeolite, bentonite clay, activated charcoal and chitosan with the brand's IMD metal-binding complex. Because each component adsorbs a different range of compounds, a blend is formulated to interact with a broader set than any single binder used alone. Binders are a long-standing category in structured supplement protocols and are typically used as part of one rather than on their own.

Described accurately, that is all a binder does: it presents a surface that compounds in the gut can stick to, so they move through the digestive tract adsorbed rather than free. It is straightforward surface chemistry, and it is worth describing it as exactly that.

Why liposomal delivery keeps coming up

Two of the four compounds above, glutathione and vitamin C, share a delivery story, and it is worth stating the principle directly because it explains a lot of what distinguishes practitioner-grade formats.

A liposome is a microscopic sphere with a shell made of phospholipids, the same class of molecule that forms cell membranes. Encapsulating a compound inside that shell does two useful things in research terms. For a fragile molecule like glutathione, it shields the intact structure from the digestive enzymes that would otherwise break it down before absorption. For a molecule like vitamin C whose absorption is capped by a saturable transport system, the liposomal carrier offers an alternative route that is not subject to the same ceiling.

The reason this matters is simple: a dose on a label is only meaningful if the molecule survives to reach circulation. For compounds where the standard oral format loses much of the dose to digestion or transport limits, the delivery system is not a marketing flourish. It is the difference between a number on a bottle and a molecule in the blood. That is the through-line connecting the absorption research across this category.

Putting the picture together

Read together, these four compounds map onto different pieces of how the body is studied to handle load and recovery. Glutathione and vitamin C sit in antioxidant defence, both facing an absorption problem that liposomal delivery is designed to address. SPMs sit in the resolution phase of the normal inflammatory response, a distinct, active process, not a suppression of inflammation. Binders sit in the gut, working by simple adsorptive chemistry.

None of these is a shortcut, and the research does not describe any of them as one. What they offer the evidence-minded reader is a clearer mental model: the same molecule can behave very differently depending on how it is delivered, and "recovery" is a set of separate, well-characterised processes rather than a single dial to turn. You can see how these fit alongside the rest of the range in the Recovery & Immune collection.

References

• Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N. Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochimica et Biophysica Acta, 2015; 1851(4):397-413. doi:10.1016/j.bbalip.2014.08.006 (PMID: 25139562)
• Davis JL, et al. Liposomal-encapsulated ascorbic acid: influence on vitamin C bioavailability and capacity to protect against ischemia-reperfusion injury. Nutrition and Metabolic Insights, 2016; 9:25-30. (PMID: 27375360)
• Levine M, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance (saturable SVCT transport). Proceedings of the National Academy of Sciences, 1996; 93(8):3704-3709. doi:10.1073/pnas.93.8.3704

This article describes findings from published research for general educational purposes. It is not medical advice, and nothing here is intended to diagnose, treat, cure, or prevent any disease. If you take prescription medication or have a health condition, consult a qualified healthcare professional before adding a supplement.